www.fdanews.com/articles/175973-oxigene-earns-orphan-drug-designation-for-pancreatic-cancer-treatment
OXiGENE Earns Orphan Drug Designation for Pancreatic Cancer Treatment
March 31, 2016
The European Commission has granted orphan drug designation to fosbretabulin for the treatment of gastro-entero-pancreatic neuroendocrine tumors.
The vascular-disrupting agent nabbed orphan drug status from the FDA earlier this year for the same indication.